BETA
UK medical device developer building GRACE, a fully implantable electric field therapy platform initially targeting glioblastoma after brain tumour surgery.
QV Bioelectronics is a UK medical device developer based at Alderley Park in Cheshire. Founded in 2018 by biomedical engineer Christopher Bullock and neurosurgeon Richard Fu, it develops implantable electric field therapy for aggressive brain tumours. Carl Daintree became CEO in March 2026, with Bullock moving to Chief Technology Officer.
Its GRACE platform is designed to be implanted during tumour resection surgery and deliver continuous therapeutic electric fields near the resection cavity. The initial target is glioblastoma. The aim is to disrupt residual cancer-cell division while reducing the daily burden associated with externally worn treatment equipment; clinical safety and effectiveness of GRACE still require evaluation.
QV disclosed £4.5 million in combined investment and grant funding in January 2026 to advance GRACE into first-in-human studies. In June it reported progress with ethics-review submissions for SHIELD, planned at Royal Melbourne Hospital in Australia. That announcement described study preparation, rather than completed enrollment or established clinical benefit.
GRACE remains a development-stage implantable therapy. QV’s June 2026 SHIELD update described final responses submitted to the Research Ethics Committee for a first-in-human study planned at Royal Melbourne Hospital, Australia. That submission is not a commercial authorization or evidence that the study has completed enrollment. [3][4][5][6]
The proposed study is intended to evaluate the fully implantable electric field therapy in patients with glioblastoma. QV’s product design and preclinical rationale do not establish clinical equivalence to other tumour treating field systems or a demonstrated survival benefit for GRACE. [3][4][5][6]
Latest recorded source review: 2026-11-05.
Scope: selected product families.
No commercially marketed product portfolio has been established in the reviewed material.
Fully implantable platform intended to deliver continuous therapeutic electric fields near residual tumour following surgical resection. GRACE stands for Glioma Resection Advanced Cavity Electric Field therapy. Development initially targets glioblastoma, with the first-in-human SHIELD study in preparation. [3]
In development · First-in-human study preparationQV reported submitting its final Research Ethics Committee responses for the planned first-in-human study at Royal Melbourne Hospital. [6]
QV announced Daintree’s appointment and co-founder Christopher Bullock’s transition to Chief Technology Officer. [5]
Combined investment and grants included PXN Ventures, Empirical Ventures, angel investors, NIHR and Innovate UK support. [7]
Christopher Bullock and Richard Fu founded QV Bioelectronics to develop implantable therapy for brain tumours. [2]
Accessed 11/05/2026